54 results
8-K
EX-99.1
VRNA
Verona Pharma plc
8 Aug 24
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
8:44am
statements include, but are not limited to, statements regarding the potential benefits, efficacy and commercial strategy for Ohtuvayre, including
8-K
EX-99.1
pdt7maxz2lay7b23d
9 May 24
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:22am
PRE 14A
vxv1c
8 Mar 24
Preliminary proxy
4:18pm
8-K
EX-99.1
xyf50ggivi5dxpa
29 Feb 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:08am
424B5
p0tz38r ev
11 Aug 22
Prospectus supplement for primary offering
5:09pm
424B5
mgl don46mb2gs1
9 Aug 22
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
2h7d85nx2hvwq
3 May 22
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
6:11am